TY  - JOUR
AU  - Ray, Kausik K
AU  - Del Prato, Stefano
AU  - Müller-Wieland, Dirk
AU  - Cariou, Bertrand
AU  - Colhoun, Helen M
AU  - Tinahones, Francisco J
AU  - Domenger, Catherine
AU  - Letierce, Alexia
AU  - Mandel, Jonas
AU  - Samuel, Rita
AU  - Bujas-Bobanovic, Maja
AU  - Leiter, Lawrence A
PY  - 2019
DO  - 10.1186/s12933-019-0951-9
UR  - http://hdl.handle.net/10668/14662
T2  - Cardiovascular diabetology
AB  - Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and LDL...
LA  - en
KW  - Alirocumab
KW  - Atherosclerotic cardiovascular disease
KW  - Dyslipidemia
KW  - Low-density lipoprotein cholesterol
KW  - Type 2 diabetes mellitus
KW  - Antibodies, Monoclonal, Humanized
KW  - Anticholesteremic Agents
KW  - Atherosclerosis
KW  - Biomarkers
KW  - Cholesterol, HDL
KW  - Cholesterol, LDL
KW  - Clinical Trials, Phase III as Topic
KW  - Clinical Trials, Phase IV as Topic
KW  - Coronary Disease
KW  - Diabetes Mellitus, Type 2
KW  - Drug Therapy, Combination
KW  - Dyslipidemias
KW  - Humans
KW  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
KW  - Multicenter Studies as Topic
KW  - PCSK9 Inhibitors
KW  - Randomized Controlled Trials as Topic
KW  - Risk Factors
KW  - Serine Proteinase Inhibitors
KW  - Time Factors
KW  - Treatment Outcome
TI  - Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
TY  - research article
VL  - 18
ER  -